Canada markets close in 20 minutes

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9800-0.0500 (-2.46%)
As of 03:35PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.0300
Open2.0200
Bid1.9800 x 1000
Ask2.0000 x 900
Day's Range1.9700 - 2.0405
52 Week Range1.9700 - 5.5000
Volume79,461
Avg. Volume470,833
Market Cap28.532M
Beta (5Y Monthly)2.46
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

    Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important bradycardia was statistically significantly lower for GencaroTM compared to metoprolol WESTMINSTER, Colo., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision med

  • GlobeNewswire

    ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

    Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potenti

  • GlobeNewswire

    ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

    WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Tom Keuer, Chief Operating Officer, will present at the Q4 Virtual Investor Summit being held November 16-17, 2021. ARCA is scheduled to present on Wednesday, November 17, 2021 at 4:15 PM ET. Management will be available for one-on-one meetings to